KalVista Pharmaceuticals Inc

Research KalVista Pharmaceuticals Inc (KALV) on Bullrun: market cap USD 1.44B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKALV
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.44B
• Financial periodFY2025
• Net income-USD 183.40M
• Free cash flow-USD 153.34M

Valuation Snapshot

latest market cap is USD 1.44B.

About KalVista Pharmaceuticals Inc

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016.

Frequently asked questions

What is KalVista Pharmaceuticals Inc's market cap?

KalVista Pharmaceuticals Inc's market capitalization is USD 1.44B.

What does KalVista Pharmaceuticals Inc do?

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets.